To unlock the proteome, scale matters.
Introducing the first large-scale, single-molecule platform designed to comprehensively quantify the proteome.
.slide-61806f638e9ea {
Introducing the first large-scale, single-molecule platform designed to comprehensively quantify the proteome.
.slide-61806f638e9ea {
Location: United States, California, San Carlos
Employees: 51-200
Total raised: $421M
Founded date: 2016
Investors 6
| Date | Name | Website |
| 02.03.2021 | Logos Capi... | logoscapit... |
| - | a16z | a16z.com/ |
| - | Madrona Ve... | madrona.co... |
| - | Defy | defy.vc |
| - | Perceptive... | perceptive... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.06.2021 | IPO | $345M | - |
| 21.05.2020 | Series B | $76M | - |
Mentions in press and media 16
| Date | Title | Description |
| 28.06.2022 | Seattle SPAC suffering: Shares of companies that went public via SPAC fall more than 50% | Seattle companies that went public via SPAC have seen their share prices drop significantly. The four Seattle businesses that went public during the SPAC boom have sputtered amid the broader economic downturn. Porch, Nautilus Biotechnology,... |
| 02.11.2021 | Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome | SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM... |
| 09.06.2021 | Sujal Patel-led Nautilus Biotechnology goes public as it tackles ambitious plan to analyze proteins | Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. (Nautilus Photo) Nautilus Biotechnology is emerging as Seattle’s newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 milli... |
| 08.02.2021 | Ally Bridge Portfolio News – Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III | Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT” Nautilus Bio... |
| 08.02.2021 | Jeff Bezos-backed startup Nautilus Biotechnology set to go public via SPAC at $900M valuation | Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. (Nautilus Photo) Nautilus Biotechnology, a Seattle-based biotech startup led by Isilon co-founder Sujal Patel, is the latest company to go public using a special purpo... |
| 08.02.2021 | Nautilus Bio lines up SPAC merger and $350M in funding for proteomics R&D | Seattle-based Nautilus is combining with Arya III, a special purpose acquisition company (SPAC), which is a publicly traded entity formed as a vehicle for other companies to go public. The combined company, which will be run by Nautilus’s m... |
| 05.01.2021 | Well-funded stealthy biotech startup Nautilus hires former Smartsheet, Isilon, GenapSys execs | From left to right: Chris Blessington, vice president of corporate marketing and communications at Nautilus; Anna Mowry, vice president of finance and business operations; and Subra Sankar, senior vice president of product development. (Nau... |
| 28.05.2020 | Human Proteome Company Nautilus Biotechnology Raises $76 Million | Nautilus Biotechnology, a company that is pioneering high-throughput and low-cost platform for analyzing and quantifying the human proteome, announced it has raised $76 million Nautilus Biotechnology, a company that is pioneering high-throu... |
| 21.05.2020 | Jeff Bezos joins $76M round for secretive biotech startup led by Isilon co-founder, Stanford scientist | Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. (Nautilus Photo) Parag Mallick spent more than 20 years studying the intersection of software engineering and life sciences to better understand predictive and persona... |
| 21.05.2020 | Nautilus emerges with $76M to become the 'Illumina of proteomics' | The vast majority of FDA-approved drugs target proteins, which makes sense because “they’re the machinery inside cells that make your body work,” says Sujal Patel, co-founder and CEO of Nautilus Biotechnology. What doesn’t make sense, he sa... |
Show more